Targeting Melanin in Melanoma with Radionuclide Therapy

Targeting Melanin in Melanoma with Radionuclide Therapy

Nearly 100,000 individuals are expected to be diagnosed with melanoma in the United States in 2022. Treatment options for late-stage metastatic disease up until the 2010s were few and offered only slight improvement to the overall survival. The introduction of B-RAF inhibitors and anti-CTLA4 and ant...

Full description

Bibliographic Details
Main Authors: Kevin J. H. Allen, Mackenzie E. Malo, Rubin Jiao, Ekaterina Dadachova
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:International Journal of Molecular Sciences
Subjects:
metastatic melanoma
radioimmunotherapy
melanin
targeted radionuclide therapy
benzamides
nicotinamides
Online Access:https://www.mdpi.com/1422-0067/23/17/9520

Similar Items

Similar Items